Diamant Thaçi
Impact in
- Dermatology top 0.01%
- Dermatology and Skin Diseases
- Immunology top 0.1%
- Psoriasis: Treatment and Pathogenesis
Papers in
- Immunology 223
- Psoriasis: Treatment and Pathogenesis 208
- Dermatology 135
- Dermatology and Skin Diseases 129
- Co-authors
- Kristian Reich (56 shared papers)Kim Papp (56 shared papers)Andrew Blauvelt (44 shared papers)Wolf‐Henning Boehncke (26 shared papers)Ralf J. Ludwig (38 shared papers)Roland Kaufmann (25 shared papers)C. Paul (19 shared papers)Emma Guttman‐Yassky (13 shared papers)
- Journals
- British Journal of Dermatology (52 papers)Journal of the American Academy of Dermatology (38 papers)Journal of the European Academy of Dermatology and Venereology (37 papers)JDDG Journal der Deutschen Dermatologischen Gesellschaft (24 papers)Dermatology and Therapy (19 papers)
- Partner nations
- GermanyUnited StatesCanada
In The Last Decade
Diamant Thaçi
346 papers receiving 13.7k citations
Diamant Thaçi's Hit Papers
Peers
Comparison fields: 5 of 124
- Dermatology 5.9k
- Immunology 7.6k
- Immunology and Allergy 1.7k
- Rheumatology 2.6k
- Pathology and Forensic Medicine 1.2k
Countries citing papers authored by Diamant Thaçi
This map shows the geographic impact of Diamant Thaçi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diamant Thaçi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diamant Thaçi more than expected).
Fields of papers citing papers by Diamant Thaçi
This network shows the impact of papers produced by Diamant Thaçi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diamant Thaçi. The network helps show where Diamant Thaçi may publish in the future.
Co-authors
The 25 scholars most cited alongside Diamant Thaçi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 385 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis Hit paper breakdown → | 2014 | 1026 |
| 2 | 2015 | 432 | |
| 3 | Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials Hit paper breakdown → | 2017 | 425 |
| 4 | 2016 | 384 | |
| 5 | Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics Hit paper breakdown → | 2013 | 380 |
| 6 | Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials Hit paper breakdown → | 2021 | 369 |
| 7 | Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t Hit paper breakdown → | 2017 | 351 |
| 8 | Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis Hit paper breakdown → | 2021 | 306 |
| 9 | 2006 | 298 | |
| 10 | 2018 | 297 | |
| 11 | Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial Hit paper breakdown → | 2019 | 261 |
| 12 | 2015 | 259 | |
| 13 | 2016 | 238 | |
| 14 | Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial Hit paper breakdown → | 2022 | 237 |
| 15 | 2015 | 228 | |
| 16 | 2019 | 222 | |
| 17 | 2013 | 210 | |
| 18 | 2007 | 203 | |
| 19 | Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial Hit paper breakdown → | 2022 | 190 |
| 20 | 2018 | 180 |
About Diamant Thaçi
Diamant Thaçi is a scholar working on Immunology, Dermatology, Rheumatology, Pathology and Forensic Medicine and Immunology and Allergy, having authored 385 papers that have together received 14.0k indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (208 papers), Dermatology and Skin Diseases (129 papers), Autoimmune Bullous Skin Diseases (36 papers), Spondyloarthritis Studies and Treatments (32 papers), Asthma and respiratory diseases (25 papers), Pharmaceutical studies and practices (22 papers), Urticaria and Related Conditions (20 papers) and Allergic Rhinitis and Sensitization (18 papers). The work is most often cited by research in Dermatology (5.9k citations), Immunology (7.6k citations), Immunology and Allergy (1.7k citations), Rheumatology (2.6k citations) and Pathology and Forensic Medicine (1.2k citations). Diamant Thaçi has collaborated with scholars based in Germany, United States and Canada. Frequent co-authors include Kristian Reich, Kim Papp, Andrew Blauvelt, Wolf‐Henning Boehncke, Ralf J. Ludwig, Roland Kaufmann, C. Paul, Emma Guttman‐Yassky, Neil M.H. Graham and Melinda Gooderham. Their work appears in journals such as British Journal of Dermatology, Journal of the American Academy of Dermatology, Journal of the European Academy of Dermatology and Venereology, JDDG Journal der Deutschen Dermatologischen Gesellschaft and Dermatology and Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.